1. In the perioperative setting, there was no difference between dd-MVAC vs. GC on overall 5-year survival. 2. In the neoadjuvant subgroup, findings from the VESPER trial revealed a notable improvement in 5-year overall survival and time to death from bladder cancer among individuals treated with dd-MVP compared to those receiving the GC regimen. Evidence